AGEN Agenus Inc

Price (delayed)

$5.69

Market cap

$1.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.1

Enterprise value

$1.31B

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the ...

Highlights
The EPS has declined by 9% since the previous quarter but it is up by 3.5% year-on-year
Agenus's debt has surged by 52% YoY
The quick ratio has plunged by 50% from the previous quarter and by 34% YoY

Key stats

What are the main financial stats of AGEN
Market
Shares outstanding
233.11M
Market cap
$1.33B
Enterprise value
$1.31B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
18.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.11
Earnings
Revenue
$68.55M
EBIT
-$160.75M
EBITDA
-$153.61M
Free cash flow
-$169.69M
Per share
EPS
-$1.1
Free cash flow per share
-$0.76
Book value per share
-$1.11
Revenue per share
$0.31
TBVPS
$0.71
Balance sheet
Total assets
$192.3M
Total liabilities
$448.05M
Debt
$56.85M
Equity
-$247.12M
Working capital
-$75.9M
Liquidity
Debt to equity
-0.23
Current ratio
0.55
Quick ratio
0.44
Net debt/EBITDA
0.11
Margins
EBITDA margin
-224.1%
Gross margin
94.9%
Net margin
-329.3%
Operating margin
-222.1%
Efficiency
Return on assets
-106.8%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-682.7%
Return on sales
-234.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGEN stock price

How has the Agenus stock price performed over time
Intraday
-3.56%
1 week
-2.23%
1 month
-9.11%
1 year
41.54%
YTD
78.93%
QTD
3.64%

Financial performance

How have Agenus's revenue and profit performed over time
Revenue
$68.55M
Gross profit
$65.06M
Operating income
-$152.24M
Net income
-$225.73M
Gross margin
94.9%
Net margin
-329.3%
AGEN's operating margin has plunged by 94% YoY and by 49% from the previous quarter
Agenus's net margin has shrunk by 90% YoY and by 47% QoQ
AGEN's operating income is down by 38% year-on-year and by 20% since the previous quarter
AGEN's net income is down by 35% YoY and by 19% QoQ

Growth

What is Agenus's growth rate over time

Valuation

What is Agenus stock price valuation
P/E
N/A
P/B
N/A
P/S
18.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.11
The EPS has declined by 9% since the previous quarter but it is up by 3.5% year-on-year
AGEN's equity is down by 30% QoQ and by 13% YoY
The stock's price to sales (P/S) is 102% more than its 5-year quarterly average of 9.5 and 100% more than its last 4 quarters average of 9.6
Agenus's revenue has decreased by 29% YoY and by 19% from the previous quarter

Efficiency

How efficient is Agenus business performance
The return on sales has dropped by 94% year-on-year and by 57% since the previous quarter
Agenus's return on assets has decreased by 18% QoQ and by 11% YoY

Dividends

What is AGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGEN.

Financial health

How did Agenus financials performed over time
AGEN's total assets is 57% lower than its total liabilities
The quick ratio has plunged by 50% from the previous quarter and by 34% YoY
Agenus's current ratio has decreased by 44% QoQ and by 26% YoY
Agenus's debt is 123% higher than its equity
Agenus's debt has surged by 52% YoY
The debt to equity has declined by 35% year-on-year but it is up by 23% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.